{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:07:07Z","timestamp":1782846427856,"version":"3.54.5"},"reference-count":20,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Surveillance is noted to be an important part of survivorship to detect recurrence and\/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n In order to inform the qualitative protocol for a larger national study, this pilot study aimed to understand the factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Semistructured interviews were conducted between October 2023 and July 2024 with purposively sampled providers involved in treating and surveilling patients with lung cancer from the US-based Palo Alto Veterans Affairs Medical Center and Stanford Medicine and its affiliate clinics. Providers were recruited through both email outreach and in-person invitations. Interviews were transcribed by an external transcription service and analyzed through a qualitative inductive content analysis approach to identify themes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 11 physicians and 2 advanced practice providers (N=13) participated in interviews. The majority were from medical specialties (n=8, 61.5%), and the average number of years of practice as a provider was 9 years. A total of 3 themes were identified that describe the clinicians\u2019 sentiments about current surveillance practices and how a risk stratification tool could be used in screening for recurrence and\/or SPLC. Clinicians consider a variety of clinical and nonclinical factors (category 1: factors that influence clinical decision making) and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (category 2: sentiments toward a hypothetical risk stratification tool). Finally, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (category 3: delivery of risk stratification data to patients).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This qualitative analysis highlights the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery. While risk stratification tools may support surveillance decisions, their further development must address data quality, accuracy across diverse clinical and nonclinical risk factors, and effective patient-level data delivery. Doing so will facilitate the practical implementation of risk stratification tools to improve surveillance of SPLC and recurrence.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/80659","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:50:09Z","timestamp":1766422209000},"page":"e80659-e80659","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the Complexity of Lung Cancer Surveillance Practices: Qualitative Pilot Study on Provider Perspectives"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4101-2653","authenticated-orcid":false,"given":"Jenny M","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-3398","authenticated-orcid":false,"given":"Sydney","family":"Conover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-6142","authenticated-orcid":false,"given":"Caroline","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-9325","authenticated-orcid":false,"given":"Shipra","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-1827","authenticated-orcid":false,"given":"Julie T","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"7","key":"R1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1200\/JCO.19.02748","article-title":"Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline","volume":"38","author":"Schneider","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"R2","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.21037\/tlcr.2019.05.07","article-title":"Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more","volume":"8","author":"Moran","journal-title":"Transl Lung Cancer Res"},{"issue":"suppl_4","key":"R3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","journal-title":"Ann Oncol"},{"issue":"12","key":"R4","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.21037\/jtd-21-1254","article-title":"Barriers to surveillance imaging adherence in early-staged lung cancer","volume":"13","author":"Bostock","journal-title":"J Thorac Dis"},{"issue":"11","key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.494","article-title":"P1.28-01 adherence to post-treatment surveillance guidelines in non-small cell lung cancer - a veteran\u2019s health administration cohort","volume":"18","author":"Randle","journal-title":"J Thorac Oncol"},{"issue":"8","key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100701","article-title":"The overlooked cornerstone in precise medicine: personalized postoperative surveillance plan for NSCLC","volume":"5","author":"Jiang","journal-title":"JTO Clin Res Rep"},{"issue":"24","key":"R7","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1002\/cncr.29677","article-title":"Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening","volume":"121","author":"Howard","journal-title":"Cancer"},{"issue":"5","key":"R8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cllc.2022.03.012","article-title":"Impact of comorbidities on lung cancer screening evaluation","volume":"23","author":"Robinson","journal-title":"Clin Lung Cancer"},{"issue":"27","key":"R9","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1200\/JCO.23.01060","article-title":"Optimizing lung cancer screening with risk prediction: current challenges and the emerging role of biomarkers","volume":"41","author":"Wu","journal-title":"JCO"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jnci\/djab138","article-title":"Development and validation of a risk prediction model for second primary lung cancer","volume":"114","author":"Choi","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"R11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19624","article-title":"Prediction-augmented shared decision-making and lung cancer screening uptake","volume":"7","author":"Caverly","journal-title":"JAMA Netw Open"},{"issue":"5","key":"R12","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1007\/s00520-021-06774-w","article-title":"Clinician perspectives on machine learning prognostic algorithms in the routine care of patients with cancer: a qualitative study","volume":"30","author":"Parikh","journal-title":"Support Care Cancer"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: An experiment with data saturation and variability","volume":"18","author":"Guest","journal-title":"Field methods"},{"issue":"13","key":"R14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","article-title":"Sample size in qualitative interview studies: guided by information power","volume":"26","author":"Malterud","journal-title":"Qual Health Res"},{"issue":"15_suppl","key":"R15","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1200\/JCO.2016.34.15_suppl.8531","article-title":"Utility of surveillance imaging in stage III non-small cell lung cancer (NSCLC) patients: A SEER-Medicare analysis","volume":"34","author":"Thakur","journal-title":"JCO"},{"issue":"3","key":"R16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/cam4.4445","article-title":"Impact of the shared decision-making process on lung cancer screening decisions","volume":"11","author":"Tan","journal-title":"Cancer Med"},{"key":"R17","unstructured":"Jaber N . Can artificial intelligence help see cancer in new, and better, ways? National Cancer Insitute. URL: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/artificial-intelligence-cancer-imaging [Accessed 22-03-2022]"},{"issue":"12","key":"R18","doi-asserted-by":"publisher","DOI":"10.3390\/life12121991","article-title":"Artificial intelligence in cancer research: trends, challenges and future directions","volume":"12","author":"Sebastian","journal-title":"Life (Basel)"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S122244","article-title":"Women\u2019s experiences and preferences regarding breast imaging after completing breast cancer treatment","volume":"11","author":"Brandzel","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"R20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043215","article-title":"Scanxiety: a scoping review about scan-associated anxiety","volume":"11","author":"Bui","journal-title":"BMJ Open"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e80659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:14:15Z","timestamp":1782843255000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e80659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.2196\/80659","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"v12i7e80659"}}